IDAMYCIN PFS Drug Patent Profile
✉ Email this page to a colleague
When do Idamycin Pfs patents expire, and what generic alternatives are available?
Idamycin Pfs is a drug marketed by Pfizer and is included in one NDA.
The generic ingredient in IDAMYCIN PFS is idarubicin hydrochloride. There are six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the idarubicin hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Idamycin Pfs
A generic version of IDAMYCIN PFS was approved as idarubicin hydrochloride by MEITHEAL on May 1st, 2002.
Summary for IDAMYCIN PFS
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 66 |
| Clinical Trials: | 31 |
| Patent Applications: | 6,273 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for IDAMYCIN PFS |
| What excipients (inactive ingredients) are in IDAMYCIN PFS? | IDAMYCIN PFS excipients list |
| DailyMed Link: | IDAMYCIN PFS at DailyMed |
Recent Clinical Trials for IDAMYCIN PFS
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Second Xiangya Hospital of Central South University | Phase 2/Phase 3 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2/Phase 3 |
| Guangzhou First People's Hospital | Phase 2/Phase 3 |
Pharmacology for IDAMYCIN PFS
| Drug Class | Anthracycline Topoisomerase Inhibitor |
| Mechanism of Action | Topoisomerase Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for IDAMYCIN PFS
US Patents and Regulatory Information for IDAMYCIN PFS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer | IDAMYCIN PFS | idarubicin hydrochloride | INJECTABLE;INJECTION | 050734-001 | Feb 17, 1997 | AP | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
